Skip to main content
Fig. 1 | BMC Musculoskeletal Disorders

Fig. 1

From: Anti-fibrotic action of pirfenidone in Dupuytren’s disease-derived fibroblasts

Fig. 1

Cell proliferative ability was diminished after the addition of Pirfenidone. (a) CT- and (b) DD-derived fibroblasts derived from four different patient samples (N = 4/group) were exposed to varying concentrations of PFD (0, 200, 400, 800 μg/ml) and TGF-β1 (10 ng/ml). Cells were then subjected to MTT assay to determine the effect of PFD on basal and TGF-β1-induced cell proliferation. Cell proliferation is displayed as absorbance values of untreated CT-derived fibroblasts normalized to 1 and compared with other treatments. Data are shown as mean ± SEM of the averages of triplicate reads for each culture derived from the four different patient samples both for CT- and DD-derived fibroblasts. Statistical analysis was performed using one-way ANOVA. *p < 0.05; **p < 0.01

Back to article page